LOGIN  |  REGISTER
Assertio

LevelJump Healthcare New CTS ER Contract Started

January 25, 2023 | Last Trade: C$0.05 0.00 0.00

Toronto, Ontario--(Newsfile Corp. - January 25, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that its' wholly owned subsidiary Canadian Teleradiology Services, Inc. ("CTS") has signed a new contract to supply its teleradiology services.

CTS has signed a new client hospital contract to provide radiology reading for overnight emergency room work. The hospital will utilize CTS radiologists to provide urgent STAT CT reading. On boarding, radiologist credentialling and IT set up is now complete and service has commenced.

This new contract is expected to increase CTS's annual revenues by between 2 to 4%.

This new contract is another example of the valuable service CTS provides to communities, especially during a time where there are staffing shortages throughout the industry. The CTS solution assists hospitals to ensure their emergency rooms continue 24/7 with critical care for patients.

"Organic growth is a key part of our strategy in addition to acquisitions," said Mitch Geisler, CEO. "We continue to increase revenues with both our telehealth solutions and in-patient care clinics. Hospitals see the benefits of our services, viewing us a strategic partner."

About LevelJump Healthcare

LevelJump Healthcare Corp., (TSXV: JUMP) is building a national telehealth medical company and brand, currently by providing teleradiology (remote radiology) services to its client hospitals and imaging centers. Additionally, JUMP owns and operates independent healthcare facilities (IHF's) focused on diagnostic imaging.

ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.

Caitlin-Robyn Densmore, Investor Relations Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.
(437) 214-1568

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).

Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB